News | October 21, 2024
Sunbird Bio raises additional US $14 million to advance Alzheimer blood tech test
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth
Abbott has recently received the US Food and Drug Administration nod to use its DBS device for treatment-resistant depression
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
The collaboration will accelerate the testing of GliaPharm’s lead molecules in preclinical models of Alzheimer’s disease and further the development of neuroimaging biomarkers
Biogen paid Ionis a US $ 60 million one-time upfront payment
Collaboration aims to develop innovative machine learning and artificial intelligence solutions for personalized and earlier treatment in neurology
Subscribe To Our Newsletter & Stay Updated
